05.30.12
Ardea Biosciences has earned a $7.5 million milestone from Bayer HealthCare under an April 2009 license agreement to develop and commercialize Ardea's mitogen-activated ERK kinase (MEK) inhibitor compounds for cancer and other indications.
The milestone was triggered by the initiation of the second phase of a previously reported Phase I/II study evaluating BAY 86-9766 in combination with gemcitabine for the treatment of advanced pancreatic cancer.
The milestone was triggered by the initiation of the second phase of a previously reported Phase I/II study evaluating BAY 86-9766 in combination with gemcitabine for the treatment of advanced pancreatic cancer.